• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biomed Environ Sci . Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19

tetano

Editor, Senior Moderator
Biomed Environ Sci


. 2021 Dec 20;34(12):976-983.
doi: 10.3967/bes2021.133.
Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19


Ling Hua Li[SUP] 1 [/SUP], Hong Wei Tu[SUP] 2 [/SUP], Dan Liang[SUP] 2 [/SUP], Chun Yan Wen[SUP] 1 [/SUP], An An Li[SUP] 3 [/SUP], Wei Yin Lin[SUP] 1 [/SUP], Ke Qi Hu[SUP] 3 [/SUP], Wen Shan Hong[SUP] 4 [/SUP], Yue Ping Li[SUP] 1 [/SUP], Juan Su[SUP] 2 [/SUP], San Tao Zhao[SUP] 1 [/SUP], Wei Li[SUP] 2 [/SUP], Run Yu Yuan[SUP] 2 [/SUP], Ping Ping Zhou[SUP] 2 [/SUP], Feng Yu Hu[SUP] 1 [/SUP], Xiao Ping Tang[SUP] 1 [/SUP], Chang Wen Ke[SUP] 2 [/SUP], Bi Xia Ke[SUP] 2 [/SUP], Wei Ping Cai[SUP] 1 [/SUP]



Affiliations

Abstract

Objective: The coronavirus disease 2019 (COVID-19) pandemic continues to present a major challenge to public health. Vaccine development requires an understanding of the kinetics of neutralizing antibody (NAb) responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Methods: In total, 605 serum samples from 125 COVID-19 patients (from January 1 to March 14, 2020) varying in age, sex, severity of symptoms, and presence of underlying diseases were collected, and antibody titers were measured using a micro-neutralization assay with wild-type SARS-CoV-2.
Results: NAbs were detectable approximately 10 days post-onset (dpo) of symptoms and peaked at approximately 20 dpo. The NAb levels were slightly higher in young males and severe cases, while no significant difference was observed for the other classifications. In follow-up cases, the NAb titer had increased or stabilized in 18 cases, whereas it had decreased in 26 cases, and in one case NAbs were undetectable at the end of our observation. Although a decreasing trend in NAb titer was observed in many cases, the NAb level was generally still protective.
Conclusion: We demonstrated that NAb levels vary among all categories of COVID-19 patients. Long-term studies are needed to determine the longevity and protective efficiency of NAbs induced by SARS-CoV-2.

Keywords: Kinetics; Neutralizing antibody; SARS-CoV-2; Sex.
 
Back
Top Bottom